Clinical Trial Update: Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial update investigating teclistamab in combination with iberdomide for relapsed or refractory multiple myeloma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)
• iberdomide (iberdomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING